相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Everolimus in colorectal cancer
Ivy Altomare et al.
EXPERT OPINION ON PHARMACOTHERAPY (2013)
Different Patterns of Akt and ERK Feedback Activation in Response to Rapamycin, Active-Site mTOR Inhibitors and Metformin in Pancreatic Cancer Cells
Heloisa P. Soares et al.
PLOS ONE (2013)
Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment
Zhihong Zeng et al.
BLOOD (2012)
Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells
Benjamin Blaser et al.
BMC CANCER (2012)
Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer
Haiyan Li et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Cancer Statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas
Feng Wei et al.
CANCER LETTERS (2012)
mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors
Yanjie Zhang et al.
CELL CYCLE (2012)
The promise of mTOR inhibitors in the treatment of colorectal cancer
Dae-Dong Kim et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
The PP242 Mammalian Target of Rapamycin (mTOR) Inhibitor Activates Extracellular Signal-regulated Kinase (ERK) in Multiple Myeloma Cells via a Target of Rapamycin Complex 1 (TORC1)/Eukaryotic Translation Initiation Factor 4E (eIF-4E)/RAF Pathway and Activation Is a Mechanism of Resistance
Bao Hoang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Dual Targeting of the Epidermal Growth Factor Receptor Using the Combination of Cetuximab and Erlotinib: Preclinical Evaluation and Results of the Phase II DUX Study in Chemotherapy-Refractory, Advanced Colorectal Cancer
Andrew J. Weickhardt et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Targeting the mTOR kinase domain: the second generation of mTOR inhibitors
Yan-Jie Zhang et al.
DRUG DISCOVERY TODAY (2011)
ERK1/2 Phosphorylate Raptor to Promote Ras-dependent Activation of mTOR Complex 1 (mTORC1)
Audrey Carriere et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
mTOR: from growth signal integration to cancer, diabetes and ageing
Roberto Zoncu et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2011)
Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling
Yonghao Yu et al.
SCIENCE (2011)
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Michelle C. Mendoza et al.
TRENDS IN BIOCHEMICAL SCIENCES (2011)
Recent Clinical Trials of mTOR-Targeted Cancer Therapies
Aruni S. Arachchige Don et al.
REVIEWS ON RECENT CLINICAL TRIALS (2011)
Updates of mTOR Inhibitors
Hongyu Zhou et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2010)
4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors
Qing-Bai She et al.
CANCER CELL (2010)
Cell Signaling by Receptor Tyrosine Kinases
Mark A. Lemmon et al.
CELL (2010)
Regulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and Stress
Shomit Sengupta et al.
MOLECULAR CELL (2010)
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
Matthew R. Janes et al.
NATURE MEDICINE (2010)
mTOR Signaling Pathway Is a Target for the Treatment of Colorectal Cancer
Yan-Jie Zhang et al.
ANNALS OF SURGICAL ONCOLOGY (2009)
Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients
Emilio Bajetta et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival
Timothy R. Peterson et al.
CELL (2009)
Targeting mTOR with rapamycin One dose does not fit all
David A. Foster et al.
CELL CYCLE (2009)
Targeted Inhibition of Mammalian Target of Rapamycin Signaling Inhibits Tumorigenesis of Colorectal Cancer
Pat Gulhati et al.
CLINICAL CANCER RESEARCH (2009)
Phase II Trial of Erlotinib and Capecitabine for Patients with Previously Untreated Metastatic Colorectal Cancer
Peter Kozuch et al.
CLINICAL COLORECTAL CANCER (2009)
An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
Carson C. Thoreen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Molecular mechanisms of mTOR-mediated translational control
Xiaoju Max Ma et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2009)
The Pharmacology of mTOR Inhibition
David A. Guertin et al.
SCIENCE SIGNALING (2009)
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Morris E. Feldman et al.
PLOS BIOLOGY (2009)
mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)
Juan M. Garcia-Martinez et al.
BIOCHEMICAL JOURNAL (2008)
Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation
Xuerong Wang et al.
CANCER RESEARCH (2008)
Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling
Tsuneo Ikenoue et al.
EMBO JOURNAL (2008)
The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C
Valeria Facchinetti et al.
EMBO JOURNAL (2008)
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors
Anne O'Donnell et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation
Andrew Y. Choo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with, metastastic colorectal cancer
J. A. Meyerhardt et al.
ANNALS OF ONCOLOGY (2007)
Emerging therapies for colorectal cancer
Aram F. Hezel et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40
Emilie Vander Haar et al.
NATURE CELL BIOLOGY (2007)
Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer
CA Townsley et al.
BRITISH JOURNAL OF CANCER (2006)
Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer
JA Meyerhardt et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
TOR signaling in growth and metabolism
S Wullschleger et al.
CELL (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
TOR signaling in growth and metabolism
Stephan Wullschleger et al.
CELL (2006)
Phosphorylation and functional inactivation of TSC2 by Erk: Implications for tuberous sclerosis and cancer pathogenesis
Li Ma et al.
CELL (2006)
Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation
A Tzatsos et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
M Moroni et al.
LANCET ONCOLOGY (2005)
ERBB receptors and cancer: The complexity of targeted inhibitors
NE Hynes et al.
NATURE REVIEWS CANCER (2005)
Phosphorylation and functional inactivation of TSC2 by Erk: Implications for tuberous sclerosis and cancer pathogenesis
L Ma et al.
CELL (2005)
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
DD Sarbassov et al.
SCIENCE (2005)
Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies
OJ Shah et al.
CURRENT BIOLOGY (2004)
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton
DD Sarbassov et al.
CURRENT BIOLOGY (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Targeting mTOR signaling for cancer therapy
S Huang et al.
CURRENT OPINION IN PHARMACOLOGY (2003)
Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control
R Loewith et al.
MOLECULAR CELL (2002)
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
K Inoki et al.
NATURE CELL BIOLOGY (2002)
Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action
K Hara et al.
CELL (2002)
TOR, a central controller of cell growth
T Schmelzle et al.
CELL (2000)
分享论文
